Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Master
WARNING LETTER
•Master•August 31, 2025

Master – FDA Warning Letter, Aug 31, 2025

Record Details

The FDA issued a Warning Letter to Master Pharmaceuticals Group on September 9, 2025, following a review of their website in August 2025. The FDA identified that the company was offering compounded drug products, specifically semaglutide and tirzepatide, with claims that were deemed false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA). These claims suggested that the compounded products were equivalent to FDA-approved drugs, which they are not, leading to their classification as misbranded. This misbranding constitutes a violation of section 301(a) of the FDCA, which prohibits the introduction of such products into interstate commerce.

The FDA has mandated that Master Pharmaceuticals Group take immediate corrective actions. These include ceasing the use of misleading language on their website and ensuring compliance with all federal regulations. The company must submit a written response within 15 working days to the Office of Compounding Quality and Compliance, detailing the steps taken to rectify the violations and prevent future occurrences. Failure to comply may result in legal actions, including product seizure and injunctions. The FDA also warned that if the company operates outside the U.S., their products could be detained or refused entry into the country. The letter underscores the company"s responsibility to ensure their operations align with federal law and FDA regulations.

Company
Master
Inspection date
August 31, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • George Tidmarsh (Director)
View Company Profile

ID · 5f0c167f-1f1e-4aa3-856a-757b7be36e75

Violation Codes10
21 U.S.C. 321(g)21 U.S.C. 321(p)21 U.S.C. 331(c)FD&C Act 201(g)FD&C Act 301(c)21 U.S.C. 352(a)FD&C Act 201(p)21 U.S.C. 352(bb)21.U.S.C. 331(a)FD&C Act 301(a)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Master
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.